The combination of herbal medicine Weng-li-tong with Tolterodine may be better than Tolterodine alone in the treatment of overactive bladder in women: a randomized placebo-controlled prospective trial.
The combination of herbal medicine Weng-li-tong with Tolterodine may be better than Tolterodine alone in the treatment of overactive bladder in women: a randomized placebo-controlled prospective trial.
复制标题
翁立通中药联合托特罗定治疗女性膀胱过度活动症可能优于单用托特罗定：一项随机安慰剂对照前瞻性试验
DOI：
10.1186/s12894-016-0167-1
复制
发表时间：
2016-08-08
期刊：
影响因子：
2
通讯作者：
Shao Y
中科院分区：
文献类型：
--
作者：
Xiao DD;Lv JW;Xie X;Jin XW;Lu MJ;Shao Y
为评价中药翁沥通（WLT）单药治疗或与托特罗定联合治疗膀胱过度活动症（OAB）的疗效和安全性，采用前瞻性、随机、单盲、多中心临床试验方法，对182例OAB患者进行安慰剂组（n= 26）、WLT组（n= 52）、托特罗定组（n = 52）或WLT+托特罗定组（n= 52）治疗。膀胱过度活动症症状评分（OABSS）和排尿行为进行了测量，以评估治疗effictiveness.ResultsIn的总数，146例[安慰剂（n= 23），WLT（n= 39），托特罗定（n= 41）和WLT加托特罗定（n= 43）]完成了8周的治疗。与安慰剂治疗组相比，三个干预组的患者在OABSS、排尿频率、平均排尿量和急迫性尿失禁方面均有显著改善。WLT在减少急迫性尿失禁方面的起效慢于托特罗定或联合治疗。与托特罗定相比，WLT改善OABSS（P= 0.022）和每日排尿次数（P= 0.034）的作用较弱。在改善OABSS、排尿频率和排尿量方面，联合治疗优于单用WLT或托特罗定。三个干预组之间的生活质量评分变化无显著差异。托特罗定组残余尿量明显增加（P= 0.004），而联合组则无明显增加。与托特罗定比较，WLT组口干（P= 0.002）、尿流弱（P= 0.002）、残余尿减少（P< 0.001）等不良反应明显减少。在改善OAB症状方面，WLT和托特罗定联合使用比托特罗定单独使用更有效。 ChiCTR-IPR-14005626 ].登记日期：2014年12月7日。
BackgroundTo assess the efficacy and safety of the herbal medicine, Weng-li-tong (WLT) as monotherapy or combined with tolterodine in women with overactive bladder (OAB).MethodsA prospective, randomized, single-blind multi-center trial was performed which included 182 OAB patients treated with either placebo (n= 26), WLT (n= 52), tolterodine (n= 52) or WLT plus tolterodine (n= 52). The overactive bladder symptom score (OABSS) and micturition behavior were measured to evaluate treatment efficacy.ResultsIn total, 146 patients [placebo (n= 23), WLT (n= 39), tolterodine (n= 41) and WLT plus tolterodine (n= 43)] completed 8 weeks of treatment. Compared to those treated with placebo, patients in three intervention groups showed significant improvements in the OABSS, voiding frequency, average voided volume and urgency incontinence. WLT had a slower onset than tolterodine or combination therapy in reducing urgency incontinence. Compared with tolterodine, WLT had a weaker effect in improving OABSS (P= 0.022) and daily voiding frequency (P= 0.034). The combination therapy had better efficacy than WLT or tolterodine alone in improving the OABSS, voiding frequency and voided volume. No significant differences in the changes in quality of life scores were observed among the three intervention groups. Residual urine increased significantly in tolterodine group (P= 0.004), but not in combination group. WLT resulted in fewer adverse effects than tolterodine such as dry mouth (P= 0.002), weak stream (P= 0.002) and less residual urine (P< 0.001).ConclusionsWLT could improve OAB symptoms in women, while it had slower onset and weaker efficacy but fewer adverse effects than tolterodine. The combination of WLT and tolterodine was more efficacious than tolterodine alone in improving OAB symptoms.Trial registrationChinese Clinical Trial Registry [ ChiCTR-IPR-14005626 ]. Date of registration: 7 December 2014.